New York State Common Retirement Fund lifted its stake in shares of Icon Plc (NASDAQ:ICLR) by 0.5% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 445,200 shares of the medical research company’s stock after purchasing an additional 2,402 shares during the quarter. New York State Common Retirement Fund owned about 0.82% of Icon worth $50,699,000 at the end of the most recent quarter.
Several other institutional investors also recently added to or reduced their stakes in the company. Shine Investment Advisory Services Inc. acquired a new stake in shares of Icon during the second quarter valued at $103,000. Acrospire Investment Management LLC boosted its stake in shares of Icon by 20.1% during the second quarter. Acrospire Investment Management LLC now owns 1,195 shares of the medical research company’s stock valued at $117,000 after acquiring an additional 200 shares during the last quarter. Parallel Advisors LLC boosted its stake in shares of Icon by 20.7% during the second quarter. Parallel Advisors LLC now owns 1,265 shares of the medical research company’s stock valued at $133,000 after acquiring an additional 217 shares during the last quarter. Sheaff Brock Investment Advisors LLC acquired a new stake in shares of Icon during the second quarter valued at $208,000. Finally, US Bancorp DE boosted its stake in shares of Icon by 17.1% during the second quarter. US Bancorp DE now owns 2,259 shares of the medical research company’s stock valued at $221,000 after acquiring an additional 330 shares during the last quarter. Institutional investors and hedge funds own 89.95% of the company’s stock.
Icon Plc (NASDAQ:ICLR) opened at $113.52 on Friday. Icon Plc has a 12-month low of $73.76 and a 12-month high of $124.48. The stock has a market capitalization of $6,166.29, a P/E ratio of 21.86, a P/E/G ratio of 1.76 and a beta of 0.56. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.90 and a current ratio of 1.90.
A number of brokerages have issued reports on ICLR. Zacks Investment Research lowered Icon from a “buy” rating to a “hold” rating in a research note on Friday, September 22nd. Jefferies Group restated a “buy” rating and issued a $122.00 price objective on shares of Icon in a report on Tuesday, September 12th. ValuEngine downgraded Icon from a “buy” rating to a “hold” rating in a report on Monday, October 2nd. Barclays raised their target price on Icon from $108.00 to $120.00 and gave the company an “equal weight” rating in a report on Friday, October 27th. Finally, Bank of America initiated coverage on Icon in a report on Monday, September 11th. They set a “buy” rating and a $128.00 target price on the stock. Four equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and two have given a strong buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $121.00.
Icon Company Profile
ICON public limited company is a contract research organization (CRO), which is engaged in providing outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company is engaged in the strategic development, management and analysis of programs that support the various stages of the clinical development process, from compound selection to Phase I-IV clinical studies.
Receive News & Ratings for Icon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon and related companies with MarketBeat.com's FREE daily email newsletter.